135 related articles for article (PubMed ID: 22969969)
1. Pilot study of neoadjuvant chemotherapy with gemcitabine and oral S-1 for resectable pancreatic cancer.
Tajima H; Ohta T; Kitagawa H; Okamoto K; Sakai S; Makino I; Kinoshita J; Furukawa H; Nakamura K; Hayashi H; Oyama K; Inokuchi M; Nakagawara H; Fujita H; Takamura H; Ninomiya I; Fushida S; Tani T; Fujimura T; Ikeda H; Kitamura S
Exp Ther Med; 2012 May; 3(5):787-792. PubMed ID: 22969969
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemotherapy with gemcitabine-based regimens improves the prognosis of node positive resectable pancreatic head cancer.
Tajima H; Ohta T; Okazaki M; Yamaguchi T; Ohbatake Y; Okamoto K; Nakanuma S; Kinoshita J; Makino I; Nakamura K; Miyashita T; Takamura H; Ninomiya I; Fushida S; Nakamura H
Mol Clin Oncol; 2019 Aug; 11(2):157-166. PubMed ID: 31281650
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of preoperative (neoadjuvant) chemotherapy with gemcitabine plus
Tajima H; Makino I; Gabata R; Okazaki M; Ohbatake Y; Shimbashi H; Nakanuma S; Saitoh H; Shimada M; Yamaguchi T; Okamoto K; Moriyama H; Kinoshita J; Nakamura K; Miyashita T; Ninomiya I; Fushida S; Ikeda H; Ohta T
Mol Clin Oncol; 2021 Feb; 14(2):26. PubMed ID: 33414907
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer.
Roland CL; Yang AD; Katz MH; Chatterjee D; Wang H; Lin H; Vauthey JN; Pisters PW; Varadhachary GR; Wolff RA; Crane CH; Lee JE; Fleming JB
Ann Surg Oncol; 2015 Apr; 22(4):1168-75. PubMed ID: 25352267
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of neoadjuvant chemotherapy with gemcitabine plus oral S-1 for resectable pancreatic cancer.
Tajima H; Kitagawa H; Tsukada T; Nakanuma S; Okamoto K; Sakai S; Makino I; Furukawa H; Nakamura K; Hayashi H; Oyama K; Inokuchi M; Nakagawara H; Miyashita T; Fujita H; Itoh H; Takamura H; Ninomiya I; Fushida S; Fujimura T; Ohta T
Mol Clin Oncol; 2013 Jul; 1(4):768-772. PubMed ID: 24649244
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Chemotherapy Enhances Local Postoperative Histopathological Tumour Stage in Borderline Resectable Pancreatic Cancer - A Matched-Pair Analysis.
Timmermann L; Rosumeck N; Klein F; Pratschke J; Pelzer U; Bahra M; Malinka T
Anticancer Res; 2019 Oct; 39(10):5781-5787. PubMed ID: 31570482
[TBL] [Abstract][Full Text] [Related]
7. Effect and limitation of neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma: consideration from a new perspective.
Kurata Y; Shiraki T; Ichinose M; Kubota K; Imai Y
World J Surg Oncol; 2021 Mar; 19(1):85. PubMed ID: 33752677
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase II trial of chemoradiotherapy with S-1 versus combination chemotherapy with gemcitabine and S-1 as neoadjuvant treatment for resectable pancreatic cancer (JASPAC 04).
Sugiura T; Toyama H; Fukutomi A; Asakura H; Takeda Y; Yamamoto K; Hirano S; Satoi S; Matsumoto I; Takahashi S; Morinaga S; Yoshida M; Sakuma Y; Iwamoto H; Shimizu Y; Uesaka K
J Hepatobiliary Pancreat Sci; 2023 Nov; 30(11):1249-1260. PubMed ID: 37746781
[TBL] [Abstract][Full Text] [Related]
9. Predictive factors of operability after neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer: a single-center retrospective study.
Murakami M; Fujimori N; Ohno A; Matsumoto K; Teramatsu K; Takamatsu Y; Takeno A; Oono T; Abe T; Ideno N; Ikenaga N; Nakata K; Nakamura M; Ishigami K; Ogawa Y
Discov Oncol; 2022 Jan; 13(1):2. PubMed ID: 35201490
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Adjuvant Chemotherapy According to the Pathological Response to Neoadjuvant Chemotherapy Among Patients With Pancreatic Ductal Adenocarcinoma.
Mori S; Aoki T; Sakuraoka Y; Shimizu T; Yamaguchi T; Park KH; Matsumoto T; Shiraki T; Iso Y; Kubota K
Anticancer Res; 2021 Mar; 41(3):1629-1639. PubMed ID: 33788759
[TBL] [Abstract][Full Text] [Related]
11. Incidence and Risk of Venous Thromboembolism in Patients With Resectable Pancreatic Cancer Receiving Neoadjuvant Chemotherapy.
Kamiya M; Kawahara S; Kamioka Y; Murakawa M; Aoyama T; Kobayashi S; Ueno M; Yamamoto N; Oshima T; Yukawa N; Rino Y; Masuda M; Morinaga S
Anticancer Res; 2023 Apr; 43(4):1741-1747. PubMed ID: 36974795
[TBL] [Abstract][Full Text] [Related]
12. Significance of neoadjuvant chemoradiotherapy for borderline resectable pancreatic head cancer: Pathological local invasion and microvessel invasion analysis.
Naito Y; Ishikawa H; Sadashima E; Okabe Y; Takahashi K; Kawahara R; Hisaka T; Fukahori M; Ushijima T; Ishida Y; Tanigawa M; Mihara Y; Nakayama M; Kondo R; Kusano H; Takase Y; Abe H; Ogo E; Okuda K; Shimamatsu K; Yano H; Akiba J
Mol Clin Oncol; 2019 Sep; 11(3):225-233. PubMed ID: 31423309
[TBL] [Abstract][Full Text] [Related]
13. A long-term survival case treated with conversion surgery following chemotherapy after diagnostic metastasectomy for pancreatic cancer with synchronous liver metastasis.
Shimura M; Mizuma M; Hayashi H; Mori A; Tachibana T; Hata T; Iseki M; Takadate T; Ariake K; Maeda S; Ohtsuka H; Sakata N; Morikawa T; Nakagawa K; Naitoh T; Kamei T; Motoi F; Unno M
Surg Case Rep; 2017 Dec; 3(1):132. PubMed ID: 29285651
[TBL] [Abstract][Full Text] [Related]
14. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages.
Gillen S; Schuster T; Meyer Zum Büschenfelde C; Friess H; Kleeff J
PLoS Med; 2010 Apr; 7(4):e1000267. PubMed ID: 20422030
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial.
Labori KJ; Lassen K; Hoem D; Grønbech JE; Søreide JA; Mortensen K; Smaaland R; Sorbye H; Verbeke C; Dueland S
BMC Surg; 2017 Aug; 17(1):94. PubMed ID: 28841916
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy with gemcitabine for pancreatic cancer increases in situ expression of the apoptosis marker M30 and stem cell marker CD44.
Tajima H; Ohta T; Kitagawa H; Okamoto K; Sakai S; Kinoshita J; Makino I; Furukawa H; Hayashi H; Nakamura K; Oyama K; Inokuchi M; Nakagawara H; Fujita H; Takamura H; Ninomiya I; Fushida S; Tani T; Fujimura T; Kitamura S; Ikeda H; Tsuneyama K
Oncol Lett; 2012 Jun; 3(6):1186-1190. PubMed ID: 22783415
[TBL] [Abstract][Full Text] [Related]
17. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery.
Nagakawa Y; Sahara Y; Hosokawa Y; Murakami Y; Yamaue H; Satoi S; Unno M; Isaji S; Endo I; Sho M; Fujii T; Takishita C; Hijikata Y; Suzuki S; Kawachi S; Katsumata K; Ohta T; Nagakawa T; Tsuchida A
Ann Surg Oncol; 2019 Jun; 26(6):1629-1636. PubMed ID: 30610555
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy for primary cutaneous/soft tissue angiosarcoma: Determining tumor behavior prior to surgical resection.
Oxenberg J; Khushalani NI; Salerno KE; Attwood K; Kane JM
J Surg Oncol; 2015 Jun; 111(7):829-33. PubMed ID: 25772798
[TBL] [Abstract][Full Text] [Related]
19. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
[No Abstract] [Full Text] [Related]
20. Oncological role of surgical resection in patients with pancreatic ductal adenocarcinoma with liver-only synchronous metastases in a single-center retrospective study.
Satoi S; Yamamoto T; Hashimoto D; Yamaki S; Matsui Y; Ikeura T; Boku S; Shibata N; Tsybulskyi D; Sekimoto M
J Gastrointest Oncol; 2023 Dec; 14(6):2587-2599. PubMed ID: 38196535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
